Literature DB >> 22811522

The breadth and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with a lower rate of mother-to-child transmission of HIV-1.

Antoine Chaillon1, Thierry Wack, Martine Braibant, Laurent Mandelbrot, Stéphane Blanche, Josiane Warszawski, Francis Barin.   

Abstract

It has been hypothesized that neutralizing antibodies (NAbs) should have broad specificity to be effective in protection against diverse HIV-1 variants. The mother-to-child transmission model of HIV-1 provides the opportunity to examine whether the breadth of maternal NAbs is associated with protection of infants from infection. Samples were obtained at delivery from 57 transmitting mothers (T) matched with 57 nontransmitting mothers (NT) enrolled in the multicenter French perinatal cohort (ANRS EPF CO1) between 1990 and 1996. Sixty-eight (59.6%) and 46 (40.4%) women were infected by B and non-B viruses, respectively. Neutralization assays were carried out with TZM-bl cells, using a panel of 10 primary isolates of 6 clades (A, B, C, F, CRF01_AE, and CRF02_AG), selected for their moderate or low sensitivity to neutralization. Neutralization breadths were not statistically different between T and NT mothers. However, a few statistically significant differences were observed, with higher frequencies or titers of NAbs toward several individual strains for NT mothers when the clade B-infected or non-clade B-infected mothers were analyzed separately. Our study confirms that the breadth of maternal NAbs is not associated with protection of infants from infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22811522      PMCID: PMC3457297          DOI: 10.1128/JVI.00518-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties.

Authors:  Suzie Thenin; Tanawan Samleerat; Elsa Tavernier; Nicole Ngo-Giang-Huong; Gonzague Jourdain; Marc Lallemant; Francis Barin; Martine Braibant
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

4.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Authors:  Dennis R Burton; Ann J Hessell; Brandon F Keele; Per Johan Klasse; Thomas A Ketas; Brian Moldt; D Cameron Dunlop; Pascal Poignard; Lara A Doyle; Lisa Cavacini; Ronald S Veazey; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

5.  Vertical HIV-1 transmission: importance of neutralizing antibody titer and specificity.

Authors:  V Bongertz; C I Costa; V G Veloso; B Grinsztejn; E C João Filho; G Calvet; J H Pilotto; M L Guimarães; M G Morgado
Journal:  Scand J Immunol       Date:  2001-03       Impact factor: 3.487

6.  The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection.

Authors:  John B Lynch; Ruth Nduati; Catherine A Blish; Barbra A Richardson; Jennifer M Mabuka; Zahra Jalalian-Lechak; Grace John-Stewart; Julie Overbaugh
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

7.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.

Authors:  Elizabeth S Russell; Jesse J Kwiek; Jessica Keys; Kirston Barton; Victor Mwapasa; David C Montefiori; Steven R Meshnick; Ronald Swanstrom
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

10.  Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding, and breast infections.

Authors:  G C John; R W Nduati; D A Mbori-Ngacha; B A Richardson; D Panteleeff; A Mwatha; J Overbaugh; J Bwayo; J O Ndinya-Achola; J K Kreiss
Journal:  J Infect Dis       Date:  2000-12-15       Impact factor: 5.226

View more
  8 in total

1.  Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120.

Authors:  Julie Matz; Pascal Kessler; Jérôme Bouchet; Olivier Combes; Oscar Henrique Pereira Ramos; Francis Barin; Daniel Baty; Loïc Martin; Serge Benichou; Patrick Chames
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

2.  Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.

Authors:  Sallie R Permar; Youyi Fong; Nathan Vandergrift; Genevieve G Fouda; Peter Gilbert; Robert Parks; Frederick H Jaeger; Justin Pollara; Amanda Martelli; Brooke E Liebl; Krissey Lloyd; Nicole L Yates; R Glenn Overman; Xiaoying Shen; Kaylan Whitaker; Haiyan Chen; Jamie Pritchett; Erika Solomon; Emma Friberg; Dawn J Marshall; John F Whitesides; Thaddeus C Gurley; Tarra Von Holle; David R Martinez; Fangping Cai; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Raul Louzao; Samantha Wilkes; Saheli Datta; Marcella Sarzotti-Kelsoe; Hua-Xin Liao; Guido Ferrari; S Munir Alam; David C Montefiori; Thomas N Denny; M Anthony Moody; Georgia D Tomaras; Feng Gao; Barton F Haynes
Journal:  J Clin Invest       Date:  2015-06-08       Impact factor: 14.808

Review 3.  Antibodies for prevention of mother-to-child transmission of HIV-1.

Authors:  Genevieve G Fouda; M Anthony Moody; Sallie R Permar
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

4.  Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.

Authors:  David R Martinez; Nathan Vandergrift; Ayooluwa O Douglas; Erin McGuire; John Bainbridge; Nathan I Nicely; David C Montefiori; Georgia D Tomaras; Genevieve G Fouda; Sallie R Permar
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

5.  Mutations that confer resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers.

Authors:  Amit Kumar; Elena E Giorgi; Joshua J Tu; David R Martinez; Joshua Eudailey; Michael Mengual; Manukumar Honnayakanahalli Marichannegowda; Russell Van Dyke; Feng Gao; Sallie R Permar
Journal:  PLoS Pathog       Date:  2021-04-02       Impact factor: 7.464

6.  HIV-1 autologous antibody neutralization associates with mother to child transmission.

Authors:  Elly Baan; Anthony de Ronde; Martijn Stax; Rogier W Sanders; Stanley Luchters; Joseph Vyankandondera; Joep M Lange; Georgios Pollakis; William A Paxton
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

Review 7.  The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?

Authors:  Martine Braibant; Francis Barin
Journal:  Retrovirology       Date:  2013-10-07       Impact factor: 4.602

8.  Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.

Authors:  Caitlin Milligan; Maxwel M Omenda; Vrasha Chohan; Katherine Odem-Davis; Barbra A Richardson; Ruth Nduati; Julie Overbaugh
Journal:  mBio       Date:  2016-02-02       Impact factor: 7.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.